EOM Pharmaceuticals Holdings, Inc. (IMUC)
OTCMKTS · Delayed Price · Currency is USD
0.1000
0.00 (0.00%)
Jul 24, 2025, 8:00 PM EDT

EOM Pharmaceuticals Holdings Company Description

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases.

Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis.

The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases.

Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

EOM Pharmaceuticals Holdings, Inc.
EOM Pharmaceuticals Holdings logo
CountryUnited States
Founded2020
IndustryBiotechnology
SectorHealthcare
Employees4
CEOIrach Taraporewala

Contact Details

Address:
136 Summit Avenue
Montvale, 07645
United States
Phone201 351 0605
Websiteeompharma.com

Stock Details

Ticker SymbolIMUC
ExchangeOTCMKTS
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberUS4525364026
SIC Code2834

Key Executives

NamePosition
Dr. Irach B. Taraporewala B.S., M.S., Ph.D.Chief Executive Officer, President and Director
Wayne I. Danson CPAChief Financial Officer and Treasurer
Eli GoldbergerFounder, Chairman and Chief Operating Officer
Dr. Shalom Z. Hirschman M.D.Co-Founder, Chief Scientific Officer and Medical Director